Latest news with #healthtechnology
National Post
a day ago
- Health
- National Post
Echo Responds to Misinformation with Science: Hydrogen Water Bottles Outperform Tablets in Safety, Efficacy, and Value
Article content SALT LAKE CITY — Echo, the global leader in hydrogen health technology, is responding forcefully to a wave of misinformation being spread by influencers with financial agendas. False claims that the Echo Flask causes heavy metals poisoning or stops working after six months are not only wrong—they're dangerous. Article content 'Hydrogen health is growing fast—and that growth has attracted a swarm of pseudo-scientific influencers using fear, not facts, to push products that pay them more money,' said Josh Carr, CEO of Echo. 'We're done letting those lies go unchallenged.' Article content At the center of the recent smear campaign are false allegations that Echo's hydrogen water bottle stops producing hydrogen after six months and may leach harmful metals. These claims are categorically false, unsupported by any lab data, and contradicted by third-party testing and thousands of happy customers. Article content The Echo Flask is engineered with platinum-coated electrodes, a proprietary proton exchange membrane, and a self-cleaning system—guaranteeing high-concentration hydrogen performance for over 10,000 uses. Echo backs every unit with a 5-year warranty and provides published test results verifying both hydrogen output and water purity. Article content 'These accusations aren't coming from scientists or doctors. They're coming from influencers who make more money when they scare people into buying hydrogen tablets,' Carr said. 'They claim our bottle causes 'heavy metals poisoning,' but produce no lab report, no data—just fear bait.' Article content Echo acknowledges that some low-end hydrogen bottles do degrade quickly—especially those built with cheap electrodes or mass-produced knockoff parts. But the Echo Flask is in a different class: medical-grade materials, clean hydrogen output, and durable construction backed by a decade of engineering. Article content In contrast, hydrogen tablets—often promoted as a better alternative—have major safety, quality, and cost issues. Many contain unregulated magnesium, along with heavy metals like lead, and begin to degrade rapidly the moment you open the package. Article content 'These tablet pushers mislead the public with confusing numbers and manipulated science,' Carr continued. 'They talk about 'high ppm levels' as if that means something useful—but hydrogen dosage is measured in milligrams, not parts per million. A high ppm in a tiny volume can mean a low actual dose. Consumers are literally paying more for less. It's dirty, expensive water with barely any usable hydrogen.' Article content Beyond misleading metrics, tablets are a recurring cost—often over $150/month to match the hydrogen levels the Echo Flask delivers for pennies per day. They're unstable, expensive, and fundamentally misrepresented. Article content 'We've tested these tablets. We've tested our bottles. We publish our data. And we stand behind our technology. That's the difference,' said Carr. 'People deserve truth—not hype.' Article content As the hydrogen wellness category continues to grow, Echo urges consumers to look past influencer theatrics and focus on science, transparency, and value. For third-party test results, hydrogen education, and Echo's full product lineup, visit Article content Article content Article content Article content
Wall Street Journal
a day ago
- Business
- Wall Street Journal
Philips Raises Full-Year Profitability Guidance on Lower Tariff Impact
Royal Philips PHIA -0.05%decrease; red down pointing triangle raised full-year profitability and cash-flow guidance as it lowered the estimated financial impact of tariffs for the year. The Dutch health-technology company said Tuesday that it now incorporates a tariff impact of between 150 million and 200 million euros ($173.9 million-$231.8 million) for the year, from a previous estimate of 250 million to 300 million euros.
Yahoo
7 days ago
- Business
- Yahoo
RingConn Gen 2 Now Available on Walmart.com, Bringing Advanced Sleep Apnea Monitoring to More Consumers
LOS ANGELES, July 23, 2025 /PRNewswire/ -- RingConn, a leading smart ring innovator, has officially launched its flagship Gen 2 Smart Ring and accessories on marking a significant milestone in its U.S. retail expansion. This partnership with Walmart, the nation's largest retailer, enhances RingConn's mission to make advanced health technology more accessible to everyday consumers. As one of the fastest-growing categories in consumer technology, smart wearable devices have become a key area of investment for Walmart, supporting improvements in employee safety, warehouse efficiency, and customer service. In response to the rising demand for personalized, preventive health tools, Walmart has steadily expanded its health-focused wearable offerings this year, adding new-generation devices and advanced sleep tracking wearables. The arrival of RingConn marks a significant step in Walmart's ongoing product diversification strategy—moving beyond traditional wrist-worn formats to offer customers a more compact, discreet, and medically insightful solution. Leveraging its leading technology and innovative design, RingConn has quickly established itself as a benchmark brand in the smart ring segment. Unique features such as advanced sleep tracking, an integrated AI health partner, and ultra-lightweight craftsmanship have earned it recognition from over 200,000 users worldwide. The United States—one of the most mature health tech markets, where consumers value data privacy and proactive health management—has long been a core focus for RingConn. The brand has seen rapid growth in the U.S., becoming a trusted name in smart rings. With its launch on RingConn will leverage Walmart's scale to reach a broad, diverse consumer base and accelerate its North American expansion. The RingConn Gen 2 Smart Ring, now available at was launched in late 2024 and broke a Kickstarter category record with $4.4 million in crowdfunding. It's the world's first smart ring to offer sleep apnea monitoring. Besides, Gen 2 holds several technical distinctions: Lightest available model at 2-3 grams, and thinnest profile in its category at 2mm Extended battery life of 10-12 days Cross-platform compatibility (Android/iOS) with no subscription fees Advanced menstrual cycle monitoring feature To ensure optimal customer experience, Walmart consumers can first order a sizing kit to determine their perfect fit before purchasing the smart ring. This partnership with Walmart marks an important step in RingConn's mission to make smart, approachable health technology available to consumers. About RingConn Established in 2021, RingConn is a leading personal health technology company dedicated to creating innovative products and services that transform the experience of maintaining personal wellness. Guided by the principle of "Hardware + Software + Services," RingConn aims to provide unique products and services for people's health. View original content to download multimedia: SOURCE RingConn LLC
Yahoo
17-07-2025
- Business
- Yahoo
Axmed and Every Pregnancy announce transformative partnership to enhance access to affordable essential medicines for mothers and babies affected by conflict and crisis
WASHINGTON, July 17, 2025 /PRNewswire/ -- Axmed, a health technology venture revolutionizing access to medicines and health products through an innovative procurement platform, and Every Pregnancy, a global, faith-based coalition that provides health services to mothers and babies affected by conflict and crisis, today announced a strategic partnership to bring affordable, quality medicines to mothers and babies who need them most. Approximately 92% of maternal deaths occur in low- and middle-income countries. In these regions, pregnant women are dying from preventable causes due to lack of access to and high costs of essential medicines and health supplies. Families in low-income countries often pay more than double for the same medicines as families in high-income settings. This new collaboration will provide Every Pregnancy partners access to affordable and quality medicines through Axmed's pioneering B2B marketplace. Together, Every Pregnancy and Axmed will break down systemic barriers that prevent medicines from reaching mothers and newborns – including fragmented supply chains, missed demand, and the limited purchasing power of local NGOs who are best positioned to meet the needs of local populations. "No mother or newborn should die simply because of where they live or how much they earn," said Emmanuel Akpakwu, Founder & CEO of Axmed. "Through our partnership with Every Pregnancy, we're combining cutting-edge procurement and supply technology with a powerful network of frontline maternal health providers to drive systemic change – faster, smarter, and at the scale this crisis demands." Through its tech-enabled procurement platform, Axmed aggregates demand from public, private, and nonprofit health care procurers, enabling bulk purchasing directly from qualified manufacturers and drastically reducing costs and improving the quality of products. By partnering with Every Pregnancy, Axmed extends its platform's reach and impact in over 20 countries with high burdens of maternal mortality – including Nigeria, Sudan, Pakistan, Palestine, and more. "This is what it looks like when community power and innovation work hand-in-hand," said Isra Chaker, CEO of Every Pregnancy. "Our collaboration with Axmed is about more than access – it's about equity, justice, and building responsive health care systems that save lives." The Axmed–Every Pregnancy partnership marks a turning point in equitable health care delivery for moms and babies, so that one day, every mother and child will have access to the quality care they deserve. About Axmed: Axmed is a technology-enabled marketplace revolutionizing how medicines and health products are sourced, financed, procured, and delivered across low- and middle-income countries. By digitizing large-scale procurement and aggregating demand across diverse procurers, Axmed enables direct access to a trusted network of local and international prequalified suppliers. Visit About Every Pregnancy: Every Pregnancy is a faith–inspired initiative committed to ensuring safe pregnancies and healthy newborns in areas impacted by conflict or crisis. The organization unites a coalition of over 40 faith–inspired philanthropists and NGOs across the U.S., U.K., Canada, Pakistan, Yemen, and beyond. Visit Media inquiries: info@ or comms@ Photo - View original content to download multimedia: SOURCE Axmed; Every Pregnancy Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
National Post
16-07-2025
- Business
- National Post
OBIO® Paves the Way for Companies to Succeed in Canada as a Stepping Stone to New Global Markets
Article content TORONTO — OBIO ®, a not-for-profit, membership-based organization offering programming and infrastructure to support early-stage and venture-backed companies, announces the launch of its Health Commercialization Access Program to accelerate the growth of Canadian biotechnology and health technology companies. The Program is supported by the Government of Canada, through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), as part of a $5-million investment in OBIO ®. Article content FedDev Ontario has long championed OBIO ® to assist high-potential health and life sciences companies to grow, scale up and attract global investment. Over the past decade, OBIO ® has enabled over 350 companies to generate in excess of $150 million in sales and $200 million in foreign direct investment. Through its Early Adopter Health Network (EAHN ™) and by accelerating technology commercialization, post-seed financing and strategic partnerships via its Capital Access Advisory Program (CAAP ®), OBIO ® has been helping Canadian innovators establish a beachhead in our publicly-funded healthcare systems. Article content Through its programming, OBIO ® identifies early-stage companies that are well-positioned to develop their businesses in Canada and expand to countries on other continents. OBIO's EAHN ™ program, which includes more than 80 healthcare organizations and health systems across Canada, has developed a pipeline of companies selling their products successfully in the Canadian market. Commercial success in Canada puts companies in a prime position to sell to international jurisdictions. Many OBIO ® affiliated-companies have already gone on to export their technologies to Europe, Indo-Pacific, Latin America and the Caribbean, and the Middle East and North Africa. Article content OBIO's Health Commercialization Access Program provides integrated CAAP ® and EAHN ™ programming for early-stage life sciences and health tech companies. This enables OBIO ® to provide its technical expertise to advise companies and allow them to leverage OBIO's extensive and expanding network of industry and health science ecosystem partners in Canada. By gaining a foothold in the Canadian market, OBIO ® enables innovators to meet the growing demand for quality, home-grown medical products and lay the foundation for a healthier future. Article content 'Congratulations to OBIO ® on the launch of the Health Commercialization Access Program,' said the Honourable Evan Solomon, Minister of Artificial Intelligence and Digital Innovation and Minister responsible for the Federal Economic Development Agency for Southern Ontario. 'This program is a powerful catalyst for Canadian innovation. OBIO ® plays a critical role in helping homegrown health tech and biotech companies turn breakthrough ideas into real-world impact. Our government is proud to support the talent, ingenuity, and ambition of Canada's innovators as they develop cutting-edge technologies that improve lives and strengthen our health system.' Article content 'We are thrilled to support early-stage life sciences and health tech companies to build a beachhead in Canada and diversify their target markets at this time of changing global trade relationships,' said Dr. Maura Campbell, President and CEO of OBIO ®. The precision psychiatry company, Mobio Interactive, has benefited from OBIO's programming to support commercialization in Canada and beyond. 'Our mission is to help create a world where anyone who is living anywhere with mental health issues has the opportunity to access clinically meaningful support,' said Dr. Bechara Saab, Mobio Interactive's CEO & Chief Scientist. 'OBIO's CAAP ® provided us with key introductions to investors whose support enabled us to lengthen our runway and scale our business. Later, we took part in OBIO's EAHN ™ to collaborate with Canadian healthcare organizations to gather real-world data on the effectiveness of our technology. Those collaborations led to sustained revenues and also provided the proof cases we needed to build partnerships in Singapore and other Asian countries.' Article content Flosonics Medical is a venture-backed start-up that develops and commercializes wearable sensors to improve the clinical management of critically ill patients inside and outside the hospital. 'EAHN ™ gave us the opportunity to evaluate our novel ultrasound technology in a real-world setting,' said Joe Eibl, CEO of Flosonics Medical, which partnered with Health Sciences North in Sudbury to conduct an accelerated study on the use of FloPatch. 'Our successful participation in the program was a pivotal moment that accelerated our path to a North American launch. Trying to raise funds and prepare for commercialization during a period of uncertainty is always challenging. Our involvement in both CAAP ® and EAHN ™ signaled to current and prospective investors that we were not only building momentum but doing so with validated clinical impact.' Article content About OBIO ® Article content Founded in 2009, OBIO ® is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to address the needs of the next generation of companies developing innovative human health products. OBIO ® supports early-stage and venture-backed life sciences and health tech companies enabling them to raise capital, hire and train industry-ready talent, facilitate the commercialization and market adoption of their technologies in health systems, and access infrastructure. OBIO® advances this goal through collaborative partnerships with industry, the investment community, academia, the healthcare system and government. For more information, please visit and follow OBIO ® on LinkedIn and X. Article content About FedDev Ontario Article content For over 15 years, the Government of Canada, through FedDev Ontario, has worked to advance and diversify the southern Ontario economy through funding opportunities and business services that support innovation, growth and job creation in Canada's most populous region. The Agency has delivered impressive results, which can be seen in southern Ontario businesses that are creating innovative technologies, improving productivity, growing revenues, creating jobs, and in the economic advancement of communities across the region. Learn more about the impact the Agency is having in southern Ontario by exploring our investment profiles, our Southern Ontario Spotlight, and FedDev Ontario's X, Facebook, Instagram and LinkedIn accounts. Article content Article content Article content Article content Article content Contacts Article content
